Table 1 Baseline characteristics of OSA individuals and non-OSA matched controls.
Characteristics | OSA individuals (n = 869) | Matched controls (n = 2,607) |
|---|---|---|
Gender, % | ||
Male | 53.62 | 53.62 |
Female | 46.38 | 46.38 |
Age, years | ||
mean ( ± SD) | 60.40 ( ± 12.24) | 60.28 ( ± 12.76) |
median [min; max] | 60 [25; 89] | 60 [20; 89] |
Types of psychotropic drugs, % | ||
Antidepressants | 62.14 | 62.14 |
Anxiolytics | 45.11 | 45.11 |
Hypnotics | 29.11 | 29.11 |
Duration of psychotropic drug treatment, % | ||
1 year | 23.01 | 23.01 |
≥2 years | 76.99 | 76.99 |
Comorbidities, % | ||
Diabetes | 23.59 | 23.63 |
Severe hypertension | 11.62 | 10.78 |
Stroke | 3.34 | 2.99 |
Annual number of physician visits, mean (SD) | ||
Visits to the general practitioner | 10.01 (6.59) | 9.67 (6.55) |
Visits to the psychiatrist | 0.68 (3.53) | 0.61 (4.38) |
Annual number of hospitalizations † | ||
mean ( ± SD) | 1.09 (5.31) | 0.98 (4.38) |
Type of end of follow-up, % | ||
CPAP discontinuation after one year | 15.88 | NA |
Death | 2.30 | 5.26 |
Lost to follow-up | 0.35 | 0.54 |
End of study period | 81.47 | 94.21 |
